サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：毒系薬剤の世界市場 - 産業規模、シェア、動向、機会、予測：動物タイプ別、由来別、治療分野別、企業別、地域別（2017年～2027年）
市場調査レポート
商品コード
1166587

毒系薬剤の世界市場 - 産業規模、シェア、動向、機会、予測：動物タイプ別、由来別、治療分野別、企業別、地域別（2017年～2027年）

Venom Based Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Animal Type, By Source, By Therapeutic Area, By Company and By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 116 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

毒系薬剤の世界市場 - 産業規模、シェア、動向、機会、予測：動物タイプ別、由来別、治療分野別、企業別、地域別（2017年～2027年）
出版日: 2022年12月01日
発行: TechSci Research
ページ情報: 英文 116 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の毒系薬剤市場は、2023年から2027年の予測期間中に目覚ましい成長を遂げると予測されています。

主な要因は、さまざまな疾患の発生率の増加、政府および民間組織による取り組みの増加などであり、これらは市場の成長を促進しています。市場の成長を支えるその他の要因としては、広範な研究開発、多数の臨床試験、認知度の向上、政府による投資、多数の有毒動物、毒系新薬の承認の容易さ、およびこの分野での技術の進歩が挙げられます。

当レポートでは、世界の毒系薬剤市場について調査し、セグメント別の分析、市場力学、企業プロファイルなどの情報を提供しています。

目次

第1章 製品概要

第2章 調査手法

第3章 世界の毒系薬剤市場に対するCOVID-19の影響

第4章 エグゼクティブサマリー

第5章 VOC (顧客の声)

  • 毒系薬剤を使用する利点
  • 毒系薬剤を製造するために一般的に使用される動物
  • 毒系薬剤の需要：治療分野別
  • 毒系薬剤の導入に対する障壁

第6章 FDAによる毒系承認薬のリスト

第7章 臨床試験分析

第8章 世界の毒系薬剤市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 動物タイプ別（ヘビ、クモ、ハチ、その他）
    • 由来別（全毒、合成、組換え、その他）
    • 治療分野別（高血圧、心血管疾患、神経疾患、疼痛管理・関節炎、その他）
    • 企業別（2021年）
    • 地域別
  • 市場マップ

第9章 北米の毒系薬剤市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 動物タイプ別
    • 由来別
    • 治療分野別
    • 国別
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第10章 欧州の毒系薬剤市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 動物タイプ別
    • 由来別
    • 治療分野別
    • 国別
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第11章 アジア太平洋の毒系薬剤市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 動物タイプ別
    • 由来別
    • 治療分野別
    • 国別
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第12章 南米の毒系薬剤市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 動物タイプ別
    • 由来別
    • 治療分野別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第13章 中東・アフリカの毒系薬剤市場の見通し

  • 市場規模と予測
    • 金額別
  • 市場シェアと予測
    • 動物タイプ別
    • 由来別
    • 治療分野別
    • 国別
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第14章 市場力学

  • 促進要因
  • 課題

第15章 市場の動向と発展

第16章 競合情勢

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pentapharm Limited
  • Medicure Inc
  • Millennium Pharmaceuticals, Inc.
  • Bausch Health Companies, Inc.
  • Novartis AG
  • Elan Pharmaceuticals, Inc.
  • Beijing Tobishi Pharmaceutical Co., Ltd.

第17章 戦略的提言

目次
Product Code: 13015

The global venom-based drugs market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing incidences of various diseases, and rise in initiatives by government and private organizations, which are curbing the growth of the market. Venom is a compound which is secreted by an animal. It is a poisonous compound which intended to harm or disable their prey or enemy. When venom is produced through organisms, it includes variety of bioactive components which produce toxic effects. Only those active components of these venoms are isolated, purified, and screened which may have desirable therapeutic properties. The other factors supporting the market's growth are, the extensive research and development, large number of clinical trials, increasing awareness, and government investments, large number of venomous animals, ease in approval of new venom-based drugs, and technological advancements in this field.

Increasing Use of Venom in Numerous Diseases

Venom derived drugs are very useful in treating various diseases such as cancer, heart attack, hypertension, acute coronary syndrome, and other, due to their potential therapeutic values, which propels the growth of the market. Several venom-based drugs are already in use such as captopril, integrilin, reptilase, exanta and others. Moreover, these venom-based drugs are used as diagnostic tools, cosmeceuticals and for drug discovery. For instance, in 2020, a study concluded that bee venom therapy might be useful in treating inflammatory forms of arthritis. Similarly, captopril is a type of drug used to cure high blood pressure and reduce the risk of heart failure after a heart attack. It is derived from a species of pit viper which is found in Brazil.

Technological Advancements and Rise in R&D activities

Owing to rising number of patients suffering from variety of diseases, the surge in demand for the treatment, is augmenting the growth of the market, globally. Various R&D activities are carried by researchers in order to treat these diseases using venom from various animals. The toxins from venom such as proteins, peptides, carbohydrates, and other components are important research tools. Subsequently, other reasons that make animal venoms attractive to researchers across the globe are the specialization, richness, and efficiency of the components present. Also, advancement in genomics, transcriptions and proteomics helps in study of these toxins, which further aids scientists to understand the venoms and their target. For instance, tozuleristide, a diagnostic drug obtained from the venom of the Israeli deathstalker scorpion, is now in clinical trials. An element of the venom, called chlorotoxin, binds to tumor cells. Researchers at the Fred Hutchinson Cancer Research Center re-engineered this protein and attached a fluorescent tag to it, resulting in a diagnostic tool that seeks out and illuminates tumors.

Market Segmentation

The global venom-based drugs market is segmented into animal type, source, therapeutic area, and company. Based on animal type, the market is divided into snake, spider, bee, and others. Based on source, the market is divided into whole venom, synthetic, recombinant, and others. Based on therapeutic area, the market is segmented into hypertension, cardiovascular diseases, neurological disorders, pain management & arthritis, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to extensive research and development on venom based drugs in the country.

Market Players

AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Pentapharm Limited Medicure Inc, Millennium Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Elan Pharmaceuticals, Inc., and Beijing Tobishi Pharmaceutical Co., Ltd. are some of the leading companies operating in the market.

Report Scope:

In this report, global venom based drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Venom Based Drugs Market, By Animal Type:

Snake

Spider

Bee

Others

  • Venom Based Drugs Market, By Source:

Whole Venom

Synthetic

Recombinant

Others

  • Venom Based Drugs Market, By Therapeutic Area:

Hypertension

Cardiovascular Diseases

Neurological Disorders

Pain Management & Arthritis

Others

  • Venom Based Drugs Market, By Region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

Australia

South Korea

Europe & CIS

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Venom Based Drugs Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Venom Based Drugs Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Benefits of Using Venom Based Drugs
  • 5.2. Commonly Used Animals for Deriving Venom Based Drugs
  • 5.3. Demand for Venom Based Drugs, By Therapeutic Area
  • 5.4. Barriers to Adoption of Venom Based Drugs

6. List of Venom Based Approved Drugs by the FDA

7. Clinical Trials Analysis

8. Global Venom Based Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type (Snake, Spider, Bee, Others)
    • 8.2.2. By Source (Whole Venom, Synthetic, Recombinant, Others)
    • 8.2.3. By Therapeutic Area (Hypertension, Cardiovascular Diseases, Neurological Disorders, Pain Management & Arthritis, Others)
    • 8.2.4. By Company (2021)
    • 8.2.5. By Region
  • 8.3. Market Map

9. North America Venom Based Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Source
    • 9.2.3. By Therapeutic Area
    • 9.2.4. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Venom Based Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Source
        • 9.3.1.2.3. By Therapeutic Area
    • 9.3.2. Mexico Venom Based Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Source
        • 9.3.2.2.3. By Therapeutic Area
    • 9.3.3. Canada Venom Based Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Source
        • 9.3.3.2.3. By Therapeutic Area

10. Europe Venom Based Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Source
    • 10.2.3. By Therapeutic Area
    • 10.2.4. By Country
  • 10.3. Europe: Country Analysis
    • 10.3.1. France Venom Based Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Source
        • 10.3.1.2.3. By Therapeutic Area
    • 10.3.2. Germany Venom Based Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Source
        • 10.3.2.2.3. By Therapeutic Area
    • 10.3.3. United Kingdom Venom Based Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Source
        • 10.3.3.2.3. By Therapeutic Area
    • 10.3.4. Italy Venom Based Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Animal Type
        • 10.3.4.2.2. By Source
        • 10.3.4.2.3. By Therapeutic Area
    • 10.3.5. Spain Venom Based Drugs Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Animal Type
        • 10.3.5.2.2. By Source
        • 10.3.5.2.3. By Therapeutic Area

11. Asia-Pacific Venom Based Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Animal Type
    • 11.2.2. By Source
    • 11.2.3. By Therapeutic Area
    • 11.2.4. By Country
  • 11.3. Asia-Pacific: Country Analysis
    • 11.3.1. China Venom Based Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Animal Type
        • 11.3.1.2.2. By Source
        • 11.3.1.2.3. By Therapeutic Area
    • 11.3.2. India Venom Based Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Animal Type
        • 11.3.2.2.2. By Source
        • 11.3.2.2.3. By Therapeutic Area
    • 11.3.3. Japan Venom Based Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Animal Type
        • 11.3.3.2.2. By Source
        • 11.3.3.2.3. By Therapeutic Area
    • 11.3.4. South Korea Venom Based Drugs Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Animal Type
        • 11.3.4.2.2. By Source
        • 11.3.4.2.3. By Therapeutic Area
    • 11.3.5. Australia Venom Based Drugs Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Animal Type
        • 11.3.5.2.2. By Source
        • 11.3.5.2.3. By Therapeutic Area

12. South America Venom Based Drugs Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Animal Type
    • 12.2.2. By Source
    • 12.2.3. By Therapeutic Area
    • 12.2.4. By Country
  • 12.3. South America: Country Analysis
    • 12.3.1. Brazil Venom Based Drugs Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Animal Type
        • 12.3.1.2.2. By Source
        • 12.3.1.2.3. By Therapeutic Area
    • 12.3.2. Argentina Venom Based Drugs Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Animal Type
        • 12.3.2.2.2. By Source
        • 12.3.2.2.3. By Therapeutic Area
    • 12.3.3. Colombia Venom Based Drugs Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Animal Type
        • 12.3.3.2.2. By Source
        • 12.3.3.2.3. By Therapeutic Area

13. Middle East and Africa Venom Based Drugs Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value
  • 13.2. Market Share & Forecast
    • 13.2.1. By Animal Type
    • 13.2.2. By Source
    • 13.2.3. By Therapeutic Area
    • 13.2.4. By Country
  • 13.3. MEA: Country Analysis
    • 13.3.1. South Africa Venom Based Drugs Market Outlook
      • 13.3.1.1. Market Size & Forecast
        • 13.3.1.1.1. By Value
      • 13.3.1.2. Market Share & Forecast
        • 13.3.1.2.1. By Animal Type
        • 13.3.1.2.2. By Source
        • 13.3.1.2.3. By Therapeutic Area
    • 13.3.2. Saudi Arabia Venom Based Drugs Market Outlook
      • 13.3.2.1. Market Size & Forecast
        • 13.3.2.1.1. By Value
      • 13.3.2.2. Market Share & Forecast
        • 13.3.2.2.1. By Animal Type
        • 13.3.2.2.2. By Source
        • 13.3.2.2.3. By Therapeutic Area
    • 13.3.3. UAE Venom Based Drugs Market Outlook
      • 13.3.3.1. Market Size & Forecast
        • 13.3.3.1.1. By Value
      • 13.3.3.2. Market Share & Forecast
        • 13.3.3.2.1. By Animal Type
        • 13.3.3.2.2. By Source
        • 13.3.3.2.3. By Therapeutic Area

14. Market Dynamics

  • 14.1. Drivers
  • 14.2. Challenges

15. Market Trends & Developments

16. Competitive Landscape

  • 16.1. AstraZeneca Plc.
  • 16.2. Bristol-Myers Squibb Company
  • 16.3. Merck & Co., Inc.
  • 16.4. Pentapharm Limited
  • 16.5. Medicure Inc
  • 16.6. Millennium Pharmaceuticals, Inc.
  • 16.7. Bausch Health Companies, Inc.
  • 16.8. Novartis AG
  • 16.9. Elan Pharmaceuticals, Inc.
  • 16.10. Beijing Tobishi Pharmaceutical Co., Ltd.

17. Strategic Recommendations